Medical Care
Global Ophthalmology Disorders Drug Market Insights, Forecast to 2030
- Mar 07, 25
- ID: 1309
- Pages: 129
- Figures: 155
- Views: 1
Macular degeneration is a group of eye disease commonly found among children and adults. There are various types of macular degeneration affecting the teens such as Cone-Rod Dystrophy, Best disease, Stargardt disease, Corneal Dystrophy, and Fuch’s Dystrophy.Retinitis pigmentosa is generally inherited from a person's parents. Mutations in one of more than 50 genes is involved.
Market Analysis and Insights: Global Ophthalmology Disorders Drug Market
The global Ophthalmology Disorders Drug market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Ophthalmology Disorders Drug is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Ophthalmology Disorders Drug is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Ophthalmology Disorders Drug is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Ophthalmology Disorders Drug include Sanofi, Bayer, Bausch + Lomb, Novartis, Usher Syndrome, Takeda Pharmaceutical, Roche, Pfizer and Allergan, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Ophthalmology Disorders Drug is widely used in various fields, such as Juvenile Macular Degeneration (Stargardt Disease), Leber Congenital Amaurosis (LCA), Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) and Usher Syndrome, etc. Juvenile Macular Degeneration (Stargardt Disease) provides greatest supports to the Ophthalmology Disorders Drug industry development. In 2023, global % revenue of Ophthalmology Disorders Drug went into Juvenile Macular Degeneration (Stargardt Disease) filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Ophthalmology Disorders Drug market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Ophthalmology Disorders Drug, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Ophthalmology Disorders Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Ophthalmology Disorders Drug revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Ophthalmology Disorders Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Ophthalmology Disorders Drug revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Sanofi
Bayer
Bausch + Lomb
Novartis
Usher Syndrome
Takeda Pharmaceutical
Roche
Pfizer
Allergan
Gilead Sciences
Kubota Pharmaceutical
Alkeus Pharmaceuticals
Astellas Pharma
Ferrer Corporate
Amgen Inc
Editas Medicine Inc
ProQR Therapeutics NV
ReNeuron
Amarantus BioScience
Ocugen
ReGenX Biosciences
Sucampo Pharmaceuticals
Orphagen Pharmaceuticals
Okuvision
Second Sight Medical
Acucela
Stealth BioTherapeutics
Sun Pharma Advanced Research Company
AmpliPhi Biosciences
Applied Genetic Technologies
Asklepios BioPharmaceutical
Biovista
Spark Therapeutics
Caladrius Biosciences
Dompe Farmaceutici
Dormant Projects
Grupo Ferrer Internacional
ID Pharma
InFlectis BioScience
Ionis Pharmaceuticals
Ixchel Pharma
Khondrion
Mimetogen Pharmaceuticals
Mitotech
M's Science
Nanovector
SanBio
Segment by Type
Oral
Injection
External Use
Segment by Application
Juvenile Macular Degeneration (Stargardt Disease)
Leber Congenital Amaurosis (LCA)
Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
Usher Syndrome
Retinitis Pigmentosa (Retinitis)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Ophthalmology Disorders Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ophthalmology Disorders Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ophthalmology Disorders Drug revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Market Analysis and Insights: Global Ophthalmology Disorders Drug Market
The global Ophthalmology Disorders Drug market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Ophthalmology Disorders Drug is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Ophthalmology Disorders Drug is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Ophthalmology Disorders Drug is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Ophthalmology Disorders Drug include Sanofi, Bayer, Bausch + Lomb, Novartis, Usher Syndrome, Takeda Pharmaceutical, Roche, Pfizer and Allergan, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Ophthalmology Disorders Drug is widely used in various fields, such as Juvenile Macular Degeneration (Stargardt Disease), Leber Congenital Amaurosis (LCA), Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) and Usher Syndrome, etc. Juvenile Macular Degeneration (Stargardt Disease) provides greatest supports to the Ophthalmology Disorders Drug industry development. In 2023, global % revenue of Ophthalmology Disorders Drug went into Juvenile Macular Degeneration (Stargardt Disease) filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Ophthalmology Disorders Drug market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Ophthalmology Disorders Drug, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Ophthalmology Disorders Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Ophthalmology Disorders Drug revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Ophthalmology Disorders Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Ophthalmology Disorders Drug revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Sanofi
Bayer
Bausch + Lomb
Novartis
Usher Syndrome
Takeda Pharmaceutical
Roche
Pfizer
Allergan
Gilead Sciences
Kubota Pharmaceutical
Alkeus Pharmaceuticals
Astellas Pharma
Ferrer Corporate
Amgen Inc
Editas Medicine Inc
ProQR Therapeutics NV
ReNeuron
Amarantus BioScience
Ocugen
ReGenX Biosciences
Sucampo Pharmaceuticals
Orphagen Pharmaceuticals
Okuvision
Second Sight Medical
Acucela
Stealth BioTherapeutics
Sun Pharma Advanced Research Company
AmpliPhi Biosciences
Applied Genetic Technologies
Asklepios BioPharmaceutical
Biovista
Spark Therapeutics
Caladrius Biosciences
Dompe Farmaceutici
Dormant Projects
Grupo Ferrer Internacional
ID Pharma
InFlectis BioScience
Ionis Pharmaceuticals
Ixchel Pharma
Khondrion
Mimetogen Pharmaceuticals
Mitotech
M's Science
Nanovector
SanBio
Segment by Type
Oral
Injection
External Use
Segment by Application
Juvenile Macular Degeneration (Stargardt Disease)
Leber Congenital Amaurosis (LCA)
Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
Usher Syndrome
Retinitis Pigmentosa (Retinitis)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Ophthalmology Disorders Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ophthalmology Disorders Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ophthalmology Disorders Drug revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Injection
1.2.4 External Use
1.3 Market by Application
1.3.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Juvenile Macular Degeneration (Stargardt Disease)
1.3.3 Leber Congenital Amaurosis (LCA)
1.3.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
1.3.5 Usher Syndrome
1.3.6 Retinitis Pigmentosa (Retinitis)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ophthalmology Disorders Drug Market Perspective (2019-2030)
2.2 Global Ophthalmology Disorders Drug Growth Trends by Region
2.2.1 Ophthalmology Disorders Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Ophthalmology Disorders Drug Historic Market Size by Region (2019-2024)
2.2.3 Ophthalmology Disorders Drug Forecasted Market Size by Region (2025-2030)
2.3 Ophthalmology Disorders Drug Market Dynamics
2.3.1 Ophthalmology Disorders Drug Industry Trends
2.3.2 Ophthalmology Disorders Drug Market Drivers
2.3.3 Ophthalmology Disorders Drug Market Challenges
2.3.4 Ophthalmology Disorders Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Ophthalmology Disorders Drug by Players
3.1.1 Global Ophthalmology Disorders Drug Revenue by Players (2019-2024)
3.1.2 Global Ophthalmology Disorders Drug Revenue Market Share by Players (2019-2024)
3.2 Global Ophthalmology Disorders Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Ophthalmology Disorders Drug, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Ophthalmology Disorders Drug Market Concentration Ratio
3.4.1 Global Ophthalmology Disorders Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ophthalmology Disorders Drug Revenue in 2023
3.5 Global Key Players of Ophthalmology Disorders Drug Head office and Area Served
3.6 Global Key Players of Ophthalmology Disorders Drug, Product and Application
3.7 Global Key Players of Ophthalmology Disorders Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Ophthalmology Disorders Drug Breakdown Data by Type
4.1 Global Ophthalmology Disorders Drug Historic Market Size by Type (2019-2024)
4.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2025-2030)
5 Ophthalmology Disorders Drug Breakdown Data by Application
5.1 Global Ophthalmology Disorders Drug Historic Market Size by Application (2019-2024)
5.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Ophthalmology Disorders Drug Market Size (2019-2030)
6.2 North America Ophthalmology Disorders Drug Market Size by Type
6.2.1 North America Ophthalmology Disorders Drug Market Size by Type (2019-2024)
6.2.2 North America Ophthalmology Disorders Drug Market Size by Type (2025-2030)
6.2.3 North America Ophthalmology Disorders Drug Market Share by Type (2019-2030)
6.3 North America Ophthalmology Disorders Drug Market Size by Application
6.3.1 North America Ophthalmology Disorders Drug Market Size by Application (2019-2024)
6.3.2 North America Ophthalmology Disorders Drug Market Size by Application (2025-2030)
6.3.3 North America Ophthalmology Disorders Drug Market Share by Application (2019-2030)
6.4 North America Ophthalmology Disorders Drug Market Size by Country
6.4.1 North America Ophthalmology Disorders Drug Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Ophthalmology Disorders Drug Market Size by Country (2019-2024)
6.4.3 North America Ophthalmology Disorders Drug Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Ophthalmology Disorders Drug Market Size (2019-2030)
7.2 Europe Ophthalmology Disorders Drug Market Size by Type
7.2.1 Europe Ophthalmology Disorders Drug Market Size by Type (2019-2024)
7.2.2 Europe Ophthalmology Disorders Drug Market Size by Type (2025-2030)
7.2.3 Europe Ophthalmology Disorders Drug Market Share by Type (2019-2030)
7.3 Europe Ophthalmology Disorders Drug Market Size by Application
7.3.1 Europe Ophthalmology Disorders Drug Market Size by Application (2019-2024)
7.3.2 Europe Ophthalmology Disorders Drug Market Size by Application (2025-2030)
7.3.3 Europe Ophthalmology Disorders Drug Market Share by Application (2019-2030)
7.4 Europe Ophthalmology Disorders Drug Market Size by Country
7.4.1 Europe Ophthalmology Disorders Drug Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Ophthalmology Disorders Drug Market Size by Country (2019-2024)
7.4.3 Europe Ophthalmology Disorders Drug Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Ophthalmology Disorders Drug Market Size (2019-2030)
8.2 China Ophthalmology Disorders Drug Market Size by Type
8.2.1 China Ophthalmology Disorders Drug Market Size by Type (2019-2024)
8.2.2 China Ophthalmology Disorders Drug Market Size by Type (2025-2030)
8.2.3 China Ophthalmology Disorders Drug Market Share by Type (2019-2030)
8.3 China Ophthalmology Disorders Drug Market Size by Application
8.3.1 China Ophthalmology Disorders Drug Market Size by Application (2019-2024)
8.3.2 China Ophthalmology Disorders Drug Market Size by Application (2025-2030)
8.3.3 China Ophthalmology Disorders Drug Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Ophthalmology Disorders Drug Market Size (2019-2030)
9.2 Asia Ophthalmology Disorders Drug Market Size by Type
9.2.1 Asia Ophthalmology Disorders Drug Market Size by Type (2019-2024)
9.2.2 Asia Ophthalmology Disorders Drug Market Size by Type (2025-2030)
9.2.3 Asia Ophthalmology Disorders Drug Market Share by Type (2019-2030)
9.3 Asia Ophthalmology Disorders Drug Market Size by Application
9.3.1 Asia Ophthalmology Disorders Drug Market Size by Application (2019-2024)
9.3.2 Asia Ophthalmology Disorders Drug Market Size by Application (2025-2030)
9.3.3 Asia Ophthalmology Disorders Drug Market Share by Application (2019-2030)
9.4 Asia Ophthalmology Disorders Drug Market Size by Region
9.4.1 Asia Ophthalmology Disorders Drug Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Ophthalmology Disorders Drug Market Size by Region (2019-2024)
9.4.3 Asia Ophthalmology Disorders Drug Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Type
10.2.1 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Application
10.3.1 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country
10.4.1 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Ophthalmology Disorders Drug Introduction
11.1.4 Sanofi Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.1.5 Sanofi Recent Developments
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Ophthalmology Disorders Drug Introduction
11.2.4 Bayer Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.2.5 Bayer Recent Developments
11.3 Bausch + Lomb
11.3.1 Bausch + Lomb Company Details
11.3.2 Bausch + Lomb Business Overview
11.3.3 Bausch + Lomb Ophthalmology Disorders Drug Introduction
11.3.4 Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.3.5 Bausch + Lomb Recent Developments
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Ophthalmology Disorders Drug Introduction
11.4.4 Novartis Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.4.5 Novartis Recent Developments
11.5 Usher Syndrome
11.5.1 Usher Syndrome Company Details
11.5.2 Usher Syndrome Business Overview
11.5.3 Usher Syndrome Ophthalmology Disorders Drug Introduction
11.5.4 Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.5.5 Usher Syndrome Recent Developments
11.6 Takeda Pharmaceutical
11.6.1 Takeda Pharmaceutical Company Details
11.6.2 Takeda Pharmaceutical Business Overview
11.6.3 Takeda Pharmaceutical Ophthalmology Disorders Drug Introduction
11.6.4 Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.6.5 Takeda Pharmaceutical Recent Developments
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Ophthalmology Disorders Drug Introduction
11.7.4 Roche Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.7.5 Roche Recent Developments
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Ophthalmology Disorders Drug Introduction
11.8.4 Pfizer Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.8.5 Pfizer Recent Developments
11.9 Allergan
11.9.1 Allergan Company Details
11.9.2 Allergan Business Overview
11.9.3 Allergan Ophthalmology Disorders Drug Introduction
11.9.4 Allergan Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.9.5 Allergan Recent Developments
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Details
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Ophthalmology Disorders Drug Introduction
11.10.4 Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.10.5 Gilead Sciences Recent Developments
11.11 Kubota Pharmaceutical
11.11.1 Kubota Pharmaceutical Company Details
11.11.2 Kubota Pharmaceutical Business Overview
11.11.3 Kubota Pharmaceutical Ophthalmology Disorders Drug Introduction
11.11.4 Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.11.5 Kubota Pharmaceutical Recent Developments
11.12 Alkeus Pharmaceuticals
11.12.1 Alkeus Pharmaceuticals Company Details
11.12.2 Alkeus Pharmaceuticals Business Overview
11.12.3 Alkeus Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.12.4 Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.12.5 Alkeus Pharmaceuticals Recent Developments
11.13 Astellas Pharma
11.13.1 Astellas Pharma Company Details
11.13.2 Astellas Pharma Business Overview
11.13.3 Astellas Pharma Ophthalmology Disorders Drug Introduction
11.13.4 Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.13.5 Astellas Pharma Recent Developments
11.14 Ferrer Corporate
11.14.1 Ferrer Corporate Company Details
11.14.2 Ferrer Corporate Business Overview
11.14.3 Ferrer Corporate Ophthalmology Disorders Drug Introduction
11.14.4 Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.14.5 Ferrer Corporate Recent Developments
11.15 Amgen Inc
11.15.1 Amgen Inc Company Details
11.15.2 Amgen Inc Business Overview
11.15.3 Amgen Inc Ophthalmology Disorders Drug Introduction
11.15.4 Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.15.5 Amgen Inc Recent Developments
11.16 Editas Medicine Inc
11.16.1 Editas Medicine Inc Company Details
11.16.2 Editas Medicine Inc Business Overview
11.16.3 Editas Medicine Inc Ophthalmology Disorders Drug Introduction
11.16.4 Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.16.5 Editas Medicine Inc Recent Developments
11.17 ProQR Therapeutics NV
11.17.1 ProQR Therapeutics NV Company Details
11.17.2 ProQR Therapeutics NV Business Overview
11.17.3 ProQR Therapeutics NV Ophthalmology Disorders Drug Introduction
11.17.4 ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.17.5 ProQR Therapeutics NV Recent Developments
11.18 ReNeuron
11.18.1 ReNeuron Company Details
11.18.2 ReNeuron Business Overview
11.18.3 ReNeuron Ophthalmology Disorders Drug Introduction
11.18.4 ReNeuron Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.18.5 ReNeuron Recent Developments
11.19 Amarantus BioScience
11.19.1 Amarantus BioScience Company Details
11.19.2 Amarantus BioScience Business Overview
11.19.3 Amarantus BioScience Ophthalmology Disorders Drug Introduction
11.19.4 Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.19.5 Amarantus BioScience Recent Developments
11.20 Ocugen
11.20.1 Ocugen Company Details
11.20.2 Ocugen Business Overview
11.20.3 Ocugen Ophthalmology Disorders Drug Introduction
11.20.4 Ocugen Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.20.5 Ocugen Recent Developments
11.21 ReGenX Biosciences
11.21.1 ReGenX Biosciences Company Details
11.21.2 ReGenX Biosciences Business Overview
11.21.3 ReGenX Biosciences Ophthalmology Disorders Drug Introduction
11.21.4 ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.21.5 ReGenX Biosciences Recent Developments
11.22 Sucampo Pharmaceuticals
11.22.1 Sucampo Pharmaceuticals Company Details
11.22.2 Sucampo Pharmaceuticals Business Overview
11.22.3 Sucampo Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.22.4 Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.22.5 Sucampo Pharmaceuticals Recent Developments
11.23 Orphagen Pharmaceuticals
11.23.1 Orphagen Pharmaceuticals Company Details
11.23.2 Orphagen Pharmaceuticals Business Overview
11.23.3 Orphagen Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.23.4 Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.23.5 Orphagen Pharmaceuticals Recent Developments
11.24 Okuvision
11.24.1 Okuvision Company Details
11.24.2 Okuvision Business Overview
11.24.3 Okuvision Ophthalmology Disorders Drug Introduction
11.24.4 Okuvision Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.24.5 Okuvision Recent Developments
11.25 Second Sight Medical
11.25.1 Second Sight Medical Company Details
11.25.2 Second Sight Medical Business Overview
11.25.3 Second Sight Medical Ophthalmology Disorders Drug Introduction
11.25.4 Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.25.5 Second Sight Medical Recent Developments
11.26 Acucela
11.26.1 Acucela Company Details
11.26.2 Acucela Business Overview
11.26.3 Acucela Ophthalmology Disorders Drug Introduction
11.26.4 Acucela Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.26.5 Acucela Recent Developments
11.27 Stealth BioTherapeutics
11.27.1 Stealth BioTherapeutics Company Details
11.27.2 Stealth BioTherapeutics Business Overview
11.27.3 Stealth BioTherapeutics Ophthalmology Disorders Drug Introduction
11.27.4 Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.27.5 Stealth BioTherapeutics Recent Developments
11.28 Sun Pharma Advanced Research Company
11.28.1 Sun Pharma Advanced Research Company Company Details
11.28.2 Sun Pharma Advanced Research Company Business Overview
11.28.3 Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Introduction
11.28.4 Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.28.5 Sun Pharma Advanced Research Company Recent Developments
11.29 AmpliPhi Biosciences
11.29.1 AmpliPhi Biosciences Company Details
11.29.2 AmpliPhi Biosciences Business Overview
11.29.3 AmpliPhi Biosciences Ophthalmology Disorders Drug Introduction
11.29.4 AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.29.5 AmpliPhi Biosciences Recent Developments
11.30 Applied Genetic Technologies
11.30.1 Applied Genetic Technologies Company Details
11.30.2 Applied Genetic Technologies Business Overview
11.30.3 Applied Genetic Technologies Ophthalmology Disorders Drug Introduction
11.30.4 Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.30.5 Applied Genetic Technologies Recent Developments
11.31 Asklepios BioPharmaceutical
11.31.1 Asklepios BioPharmaceutical Company Details
11.31.2 Asklepios BioPharmaceutical Business Overview
11.31.3 Asklepios BioPharmaceutical Ophthalmology Disorders Drug Introduction
11.31.4 Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.31.5 Asklepios BioPharmaceutical Recent Developments
11.32 Biovista
11.32.1 Biovista Company Details
11.32.2 Biovista Business Overview
11.32.3 Biovista Ophthalmology Disorders Drug Introduction
11.32.4 Biovista Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.32.5 Biovista Recent Developments
11.33 Spark Therapeutics
11.33.1 Spark Therapeutics Company Details
11.33.2 Spark Therapeutics Business Overview
11.33.3 Spark Therapeutics Ophthalmology Disorders Drug Introduction
11.33.4 Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.33.5 Spark Therapeutics Recent Developments
11.34 Caladrius Biosciences
11.34.1 Caladrius Biosciences Company Details
11.34.2 Caladrius Biosciences Business Overview
11.34.3 Caladrius Biosciences Ophthalmology Disorders Drug Introduction
11.34.4 Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.34.5 Caladrius Biosciences Recent Developments
11.35 Dompe Farmaceutici
11.35.1 Dompe Farmaceutici Company Details
11.35.2 Dompe Farmaceutici Business Overview
11.35.3 Dompe Farmaceutici Ophthalmology Disorders Drug Introduction
11.35.4 Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.35.5 Dompe Farmaceutici Recent Developments
11.36 Dormant Projects
11.36.1 Dormant Projects Company Details
11.36.2 Dormant Projects Business Overview
11.36.3 Dormant Projects Ophthalmology Disorders Drug Introduction
11.36.4 Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.36.5 Dormant Projects Recent Developments
11.37 Grupo Ferrer Internacional
11.37.1 Grupo Ferrer Internacional Company Details
11.37.2 Grupo Ferrer Internacional Business Overview
11.37.3 Grupo Ferrer Internacional Ophthalmology Disorders Drug Introduction
11.37.4 Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.37.5 Grupo Ferrer Internacional Recent Developments
11.38 ID Pharma
11.38.1 ID Pharma Company Details
11.38.2 ID Pharma Business Overview
11.38.3 ID Pharma Ophthalmology Disorders Drug Introduction
11.38.4 ID Pharma Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.38.5 ID Pharma Recent Developments
11.39 InFlectis BioScience
11.39.1 InFlectis BioScience Company Details
11.39.2 InFlectis BioScience Business Overview
11.39.3 InFlectis BioScience Ophthalmology Disorders Drug Introduction
11.39.4 InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.39.5 InFlectis BioScience Recent Developments
11.40 Ionis Pharmaceuticals
11.40.1 Ionis Pharmaceuticals Company Details
11.40.2 Ionis Pharmaceuticals Business Overview
11.40.3 Ionis Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.40.4 Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.40.5 Ionis Pharmaceuticals Recent Developments
11.41 Ixchel Pharma
11.42 Khondrion
11.43 Mimetogen Pharmaceuticals
11.44 Mitotech
11.45 M's Science
11.46 Nanovector
11.47 SanBio
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Injection
1.2.4 External Use
1.3 Market by Application
1.3.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Juvenile Macular Degeneration (Stargardt Disease)
1.3.3 Leber Congenital Amaurosis (LCA)
1.3.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
1.3.5 Usher Syndrome
1.3.6 Retinitis Pigmentosa (Retinitis)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ophthalmology Disorders Drug Market Perspective (2019-2030)
2.2 Global Ophthalmology Disorders Drug Growth Trends by Region
2.2.1 Ophthalmology Disorders Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Ophthalmology Disorders Drug Historic Market Size by Region (2019-2024)
2.2.3 Ophthalmology Disorders Drug Forecasted Market Size by Region (2025-2030)
2.3 Ophthalmology Disorders Drug Market Dynamics
2.3.1 Ophthalmology Disorders Drug Industry Trends
2.3.2 Ophthalmology Disorders Drug Market Drivers
2.3.3 Ophthalmology Disorders Drug Market Challenges
2.3.4 Ophthalmology Disorders Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Ophthalmology Disorders Drug by Players
3.1.1 Global Ophthalmology Disorders Drug Revenue by Players (2019-2024)
3.1.2 Global Ophthalmology Disorders Drug Revenue Market Share by Players (2019-2024)
3.2 Global Ophthalmology Disorders Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Ophthalmology Disorders Drug, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Ophthalmology Disorders Drug Market Concentration Ratio
3.4.1 Global Ophthalmology Disorders Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ophthalmology Disorders Drug Revenue in 2023
3.5 Global Key Players of Ophthalmology Disorders Drug Head office and Area Served
3.6 Global Key Players of Ophthalmology Disorders Drug, Product and Application
3.7 Global Key Players of Ophthalmology Disorders Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Ophthalmology Disorders Drug Breakdown Data by Type
4.1 Global Ophthalmology Disorders Drug Historic Market Size by Type (2019-2024)
4.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2025-2030)
5 Ophthalmology Disorders Drug Breakdown Data by Application
5.1 Global Ophthalmology Disorders Drug Historic Market Size by Application (2019-2024)
5.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Ophthalmology Disorders Drug Market Size (2019-2030)
6.2 North America Ophthalmology Disorders Drug Market Size by Type
6.2.1 North America Ophthalmology Disorders Drug Market Size by Type (2019-2024)
6.2.2 North America Ophthalmology Disorders Drug Market Size by Type (2025-2030)
6.2.3 North America Ophthalmology Disorders Drug Market Share by Type (2019-2030)
6.3 North America Ophthalmology Disorders Drug Market Size by Application
6.3.1 North America Ophthalmology Disorders Drug Market Size by Application (2019-2024)
6.3.2 North America Ophthalmology Disorders Drug Market Size by Application (2025-2030)
6.3.3 North America Ophthalmology Disorders Drug Market Share by Application (2019-2030)
6.4 North America Ophthalmology Disorders Drug Market Size by Country
6.4.1 North America Ophthalmology Disorders Drug Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Ophthalmology Disorders Drug Market Size by Country (2019-2024)
6.4.3 North America Ophthalmology Disorders Drug Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Ophthalmology Disorders Drug Market Size (2019-2030)
7.2 Europe Ophthalmology Disorders Drug Market Size by Type
7.2.1 Europe Ophthalmology Disorders Drug Market Size by Type (2019-2024)
7.2.2 Europe Ophthalmology Disorders Drug Market Size by Type (2025-2030)
7.2.3 Europe Ophthalmology Disorders Drug Market Share by Type (2019-2030)
7.3 Europe Ophthalmology Disorders Drug Market Size by Application
7.3.1 Europe Ophthalmology Disorders Drug Market Size by Application (2019-2024)
7.3.2 Europe Ophthalmology Disorders Drug Market Size by Application (2025-2030)
7.3.3 Europe Ophthalmology Disorders Drug Market Share by Application (2019-2030)
7.4 Europe Ophthalmology Disorders Drug Market Size by Country
7.4.1 Europe Ophthalmology Disorders Drug Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Ophthalmology Disorders Drug Market Size by Country (2019-2024)
7.4.3 Europe Ophthalmology Disorders Drug Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Ophthalmology Disorders Drug Market Size (2019-2030)
8.2 China Ophthalmology Disorders Drug Market Size by Type
8.2.1 China Ophthalmology Disorders Drug Market Size by Type (2019-2024)
8.2.2 China Ophthalmology Disorders Drug Market Size by Type (2025-2030)
8.2.3 China Ophthalmology Disorders Drug Market Share by Type (2019-2030)
8.3 China Ophthalmology Disorders Drug Market Size by Application
8.3.1 China Ophthalmology Disorders Drug Market Size by Application (2019-2024)
8.3.2 China Ophthalmology Disorders Drug Market Size by Application (2025-2030)
8.3.3 China Ophthalmology Disorders Drug Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Ophthalmology Disorders Drug Market Size (2019-2030)
9.2 Asia Ophthalmology Disorders Drug Market Size by Type
9.2.1 Asia Ophthalmology Disorders Drug Market Size by Type (2019-2024)
9.2.2 Asia Ophthalmology Disorders Drug Market Size by Type (2025-2030)
9.2.3 Asia Ophthalmology Disorders Drug Market Share by Type (2019-2030)
9.3 Asia Ophthalmology Disorders Drug Market Size by Application
9.3.1 Asia Ophthalmology Disorders Drug Market Size by Application (2019-2024)
9.3.2 Asia Ophthalmology Disorders Drug Market Size by Application (2025-2030)
9.3.3 Asia Ophthalmology Disorders Drug Market Share by Application (2019-2030)
9.4 Asia Ophthalmology Disorders Drug Market Size by Region
9.4.1 Asia Ophthalmology Disorders Drug Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Ophthalmology Disorders Drug Market Size by Region (2019-2024)
9.4.3 Asia Ophthalmology Disorders Drug Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Type
10.2.1 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Application
10.3.1 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country
10.4.1 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Ophthalmology Disorders Drug Introduction
11.1.4 Sanofi Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.1.5 Sanofi Recent Developments
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Ophthalmology Disorders Drug Introduction
11.2.4 Bayer Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.2.5 Bayer Recent Developments
11.3 Bausch + Lomb
11.3.1 Bausch + Lomb Company Details
11.3.2 Bausch + Lomb Business Overview
11.3.3 Bausch + Lomb Ophthalmology Disorders Drug Introduction
11.3.4 Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.3.5 Bausch + Lomb Recent Developments
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Ophthalmology Disorders Drug Introduction
11.4.4 Novartis Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.4.5 Novartis Recent Developments
11.5 Usher Syndrome
11.5.1 Usher Syndrome Company Details
11.5.2 Usher Syndrome Business Overview
11.5.3 Usher Syndrome Ophthalmology Disorders Drug Introduction
11.5.4 Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.5.5 Usher Syndrome Recent Developments
11.6 Takeda Pharmaceutical
11.6.1 Takeda Pharmaceutical Company Details
11.6.2 Takeda Pharmaceutical Business Overview
11.6.3 Takeda Pharmaceutical Ophthalmology Disorders Drug Introduction
11.6.4 Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.6.5 Takeda Pharmaceutical Recent Developments
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Ophthalmology Disorders Drug Introduction
11.7.4 Roche Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.7.5 Roche Recent Developments
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Ophthalmology Disorders Drug Introduction
11.8.4 Pfizer Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.8.5 Pfizer Recent Developments
11.9 Allergan
11.9.1 Allergan Company Details
11.9.2 Allergan Business Overview
11.9.3 Allergan Ophthalmology Disorders Drug Introduction
11.9.4 Allergan Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.9.5 Allergan Recent Developments
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Details
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Ophthalmology Disorders Drug Introduction
11.10.4 Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.10.5 Gilead Sciences Recent Developments
11.11 Kubota Pharmaceutical
11.11.1 Kubota Pharmaceutical Company Details
11.11.2 Kubota Pharmaceutical Business Overview
11.11.3 Kubota Pharmaceutical Ophthalmology Disorders Drug Introduction
11.11.4 Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.11.5 Kubota Pharmaceutical Recent Developments
11.12 Alkeus Pharmaceuticals
11.12.1 Alkeus Pharmaceuticals Company Details
11.12.2 Alkeus Pharmaceuticals Business Overview
11.12.3 Alkeus Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.12.4 Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.12.5 Alkeus Pharmaceuticals Recent Developments
11.13 Astellas Pharma
11.13.1 Astellas Pharma Company Details
11.13.2 Astellas Pharma Business Overview
11.13.3 Astellas Pharma Ophthalmology Disorders Drug Introduction
11.13.4 Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.13.5 Astellas Pharma Recent Developments
11.14 Ferrer Corporate
11.14.1 Ferrer Corporate Company Details
11.14.2 Ferrer Corporate Business Overview
11.14.3 Ferrer Corporate Ophthalmology Disorders Drug Introduction
11.14.4 Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.14.5 Ferrer Corporate Recent Developments
11.15 Amgen Inc
11.15.1 Amgen Inc Company Details
11.15.2 Amgen Inc Business Overview
11.15.3 Amgen Inc Ophthalmology Disorders Drug Introduction
11.15.4 Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.15.5 Amgen Inc Recent Developments
11.16 Editas Medicine Inc
11.16.1 Editas Medicine Inc Company Details
11.16.2 Editas Medicine Inc Business Overview
11.16.3 Editas Medicine Inc Ophthalmology Disorders Drug Introduction
11.16.4 Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.16.5 Editas Medicine Inc Recent Developments
11.17 ProQR Therapeutics NV
11.17.1 ProQR Therapeutics NV Company Details
11.17.2 ProQR Therapeutics NV Business Overview
11.17.3 ProQR Therapeutics NV Ophthalmology Disorders Drug Introduction
11.17.4 ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.17.5 ProQR Therapeutics NV Recent Developments
11.18 ReNeuron
11.18.1 ReNeuron Company Details
11.18.2 ReNeuron Business Overview
11.18.3 ReNeuron Ophthalmology Disorders Drug Introduction
11.18.4 ReNeuron Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.18.5 ReNeuron Recent Developments
11.19 Amarantus BioScience
11.19.1 Amarantus BioScience Company Details
11.19.2 Amarantus BioScience Business Overview
11.19.3 Amarantus BioScience Ophthalmology Disorders Drug Introduction
11.19.4 Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.19.5 Amarantus BioScience Recent Developments
11.20 Ocugen
11.20.1 Ocugen Company Details
11.20.2 Ocugen Business Overview
11.20.3 Ocugen Ophthalmology Disorders Drug Introduction
11.20.4 Ocugen Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.20.5 Ocugen Recent Developments
11.21 ReGenX Biosciences
11.21.1 ReGenX Biosciences Company Details
11.21.2 ReGenX Biosciences Business Overview
11.21.3 ReGenX Biosciences Ophthalmology Disorders Drug Introduction
11.21.4 ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.21.5 ReGenX Biosciences Recent Developments
11.22 Sucampo Pharmaceuticals
11.22.1 Sucampo Pharmaceuticals Company Details
11.22.2 Sucampo Pharmaceuticals Business Overview
11.22.3 Sucampo Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.22.4 Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.22.5 Sucampo Pharmaceuticals Recent Developments
11.23 Orphagen Pharmaceuticals
11.23.1 Orphagen Pharmaceuticals Company Details
11.23.2 Orphagen Pharmaceuticals Business Overview
11.23.3 Orphagen Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.23.4 Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.23.5 Orphagen Pharmaceuticals Recent Developments
11.24 Okuvision
11.24.1 Okuvision Company Details
11.24.2 Okuvision Business Overview
11.24.3 Okuvision Ophthalmology Disorders Drug Introduction
11.24.4 Okuvision Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.24.5 Okuvision Recent Developments
11.25 Second Sight Medical
11.25.1 Second Sight Medical Company Details
11.25.2 Second Sight Medical Business Overview
11.25.3 Second Sight Medical Ophthalmology Disorders Drug Introduction
11.25.4 Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.25.5 Second Sight Medical Recent Developments
11.26 Acucela
11.26.1 Acucela Company Details
11.26.2 Acucela Business Overview
11.26.3 Acucela Ophthalmology Disorders Drug Introduction
11.26.4 Acucela Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.26.5 Acucela Recent Developments
11.27 Stealth BioTherapeutics
11.27.1 Stealth BioTherapeutics Company Details
11.27.2 Stealth BioTherapeutics Business Overview
11.27.3 Stealth BioTherapeutics Ophthalmology Disorders Drug Introduction
11.27.4 Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.27.5 Stealth BioTherapeutics Recent Developments
11.28 Sun Pharma Advanced Research Company
11.28.1 Sun Pharma Advanced Research Company Company Details
11.28.2 Sun Pharma Advanced Research Company Business Overview
11.28.3 Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Introduction
11.28.4 Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.28.5 Sun Pharma Advanced Research Company Recent Developments
11.29 AmpliPhi Biosciences
11.29.1 AmpliPhi Biosciences Company Details
11.29.2 AmpliPhi Biosciences Business Overview
11.29.3 AmpliPhi Biosciences Ophthalmology Disorders Drug Introduction
11.29.4 AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.29.5 AmpliPhi Biosciences Recent Developments
11.30 Applied Genetic Technologies
11.30.1 Applied Genetic Technologies Company Details
11.30.2 Applied Genetic Technologies Business Overview
11.30.3 Applied Genetic Technologies Ophthalmology Disorders Drug Introduction
11.30.4 Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.30.5 Applied Genetic Technologies Recent Developments
11.31 Asklepios BioPharmaceutical
11.31.1 Asklepios BioPharmaceutical Company Details
11.31.2 Asklepios BioPharmaceutical Business Overview
11.31.3 Asklepios BioPharmaceutical Ophthalmology Disorders Drug Introduction
11.31.4 Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.31.5 Asklepios BioPharmaceutical Recent Developments
11.32 Biovista
11.32.1 Biovista Company Details
11.32.2 Biovista Business Overview
11.32.3 Biovista Ophthalmology Disorders Drug Introduction
11.32.4 Biovista Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.32.5 Biovista Recent Developments
11.33 Spark Therapeutics
11.33.1 Spark Therapeutics Company Details
11.33.2 Spark Therapeutics Business Overview
11.33.3 Spark Therapeutics Ophthalmology Disorders Drug Introduction
11.33.4 Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.33.5 Spark Therapeutics Recent Developments
11.34 Caladrius Biosciences
11.34.1 Caladrius Biosciences Company Details
11.34.2 Caladrius Biosciences Business Overview
11.34.3 Caladrius Biosciences Ophthalmology Disorders Drug Introduction
11.34.4 Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.34.5 Caladrius Biosciences Recent Developments
11.35 Dompe Farmaceutici
11.35.1 Dompe Farmaceutici Company Details
11.35.2 Dompe Farmaceutici Business Overview
11.35.3 Dompe Farmaceutici Ophthalmology Disorders Drug Introduction
11.35.4 Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.35.5 Dompe Farmaceutici Recent Developments
11.36 Dormant Projects
11.36.1 Dormant Projects Company Details
11.36.2 Dormant Projects Business Overview
11.36.3 Dormant Projects Ophthalmology Disorders Drug Introduction
11.36.4 Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.36.5 Dormant Projects Recent Developments
11.37 Grupo Ferrer Internacional
11.37.1 Grupo Ferrer Internacional Company Details
11.37.2 Grupo Ferrer Internacional Business Overview
11.37.3 Grupo Ferrer Internacional Ophthalmology Disorders Drug Introduction
11.37.4 Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.37.5 Grupo Ferrer Internacional Recent Developments
11.38 ID Pharma
11.38.1 ID Pharma Company Details
11.38.2 ID Pharma Business Overview
11.38.3 ID Pharma Ophthalmology Disorders Drug Introduction
11.38.4 ID Pharma Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.38.5 ID Pharma Recent Developments
11.39 InFlectis BioScience
11.39.1 InFlectis BioScience Company Details
11.39.2 InFlectis BioScience Business Overview
11.39.3 InFlectis BioScience Ophthalmology Disorders Drug Introduction
11.39.4 InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.39.5 InFlectis BioScience Recent Developments
11.40 Ionis Pharmaceuticals
11.40.1 Ionis Pharmaceuticals Company Details
11.40.2 Ionis Pharmaceuticals Business Overview
11.40.3 Ionis Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.40.4 Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.40.5 Ionis Pharmaceuticals Recent Developments
11.41 Ixchel Pharma
11.42 Khondrion
11.43 Mimetogen Pharmaceuticals
11.44 Mitotech
11.45 M's Science
11.46 Nanovector
11.47 SanBio
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Ophthalmology Disorders Drug Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of Oral
Table 3. Key Players of Injection
Table 4. Key Players of External Use
Table 5. Global Ophthalmology Disorders Drug Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 6. Global Ophthalmology Disorders Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Ophthalmology Disorders Drug Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Ophthalmology Disorders Drug Market Share by Region (2019-2024)
Table 9. Global Ophthalmology Disorders Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Ophthalmology Disorders Drug Market Share by Region (2025-2030)
Table 11. Ophthalmology Disorders Drug Market Trends
Table 12. Ophthalmology Disorders Drug Market Drivers
Table 13. Ophthalmology Disorders Drug Market Challenges
Table 14. Ophthalmology Disorders Drug Market Restraints
Table 15. Global Ophthalmology Disorders Drug Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Ophthalmology Disorders Drug Revenue Share by Players (2019-2024)
Table 17. Global Top Ophthalmology Disorders Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ophthalmology Disorders Drug as of 2023)
Table 18. Global Ophthalmology Disorders Drug Industry Ranking 2022 VS 2023 VS 2024
Table 19. Global 5 Largest Players Market Share by Ophthalmology Disorders Drug Revenue (CR5 and HHI) & (2019-2024)
Table 20. Global Key Players of Ophthalmology Disorders Drug, Headquarters and Area Served
Table 21. Global Key Players of Ophthalmology Disorders Drug, Product and Application
Table 22. Global Key Players of Ophthalmology Disorders Drug, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2019-2024)
Table 26. Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2025-2030)
Table 28. Global Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Ophthalmology Disorders Drug Revenue Share by Application (2019-2024)
Table 30. Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Ophthalmology Disorders Drug Revenue Share by Application (2025-2030)
Table 32. North America Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 33. North America Ophthalmology Disorders Drug Market Size by Type (2025-2030) & (US$ Million)
Table 34. North America Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 35. North America Ophthalmology Disorders Drug Market Size by Application (2025-2030) & (US$ Million)
Table 36. North America Ophthalmology Disorders Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Ophthalmology Disorders Drug Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Ophthalmology Disorders Drug Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 40. Europe Ophthalmology Disorders Drug Market Size by Type (2025-2030) & (US$ Million)
Table 41. Europe Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 42. Europe Ophthalmology Disorders Drug Market Size by Application (2025-2030) & (US$ Million)
Table 43. Europe Ophthalmology Disorders Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Europe Ophthalmology Disorders Drug Market Size by Country (2019-2024) & (US$ Million)
Table 45. Europe Ophthalmology Disorders Drug Market Size by Country (2025-2030) & (US$ Million)
Table 46. China Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 47. China Ophthalmology Disorders Drug Market Size by Type (2025-2030) & (US$ Million)
Table 48. China Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 49. China Ophthalmology Disorders Drug Market Size by Application (2025-2030) & (US$ Million)
Table 50. Asia Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 51. Asia Ophthalmology Disorders Drug Market Size by Type (2025-2030) & (US$ Million)
Table 52. Asia Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 53. Asia Ophthalmology Disorders Drug Market Size by Application (2025-2030) & (US$ Million)
Table 54. Asia Ophthalmology Disorders Drug Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 55. Asia Ophthalmology Disorders Drug Market Size by Region (2019-2024) & (US$ Million)
Table 56. Asia Ophthalmology Disorders Drug Market Size by Region (2025-2030) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Type (2025-2030) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Application (2025-2030) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 62. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country (2019-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country (2025-2030) & (US$ Million)
Table 64. Sanofi Company Details
Table 65. Sanofi Business Overview
Table 66. Sanofi Ophthalmology Disorders Drug Product
Table 67. Sanofi Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 68. Sanofi Recent Developments
Table 69. Bayer Company Details
Table 70. Bayer Business Overview
Table 71. Bayer Ophthalmology Disorders Drug Product
Table 72. Bayer Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 73. Bayer Recent Developments
Table 74. Bausch + Lomb Company Details
Table 75. Bausch + Lomb Business Overview
Table 76. Bausch + Lomb Ophthalmology Disorders Drug Product
Table 77. Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 78. Bausch + Lomb Recent Developments
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Ophthalmology Disorders Drug Product
Table 82. Novartis Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 83. Novartis Recent Developments
Table 84. Usher Syndrome Company Details
Table 85. Usher Syndrome Business Overview
Table 86. Usher Syndrome Ophthalmology Disorders Drug Product
Table 87. Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 88. Usher Syndrome Recent Developments
Table 89. Takeda Pharmaceutical Company Details
Table 90. Takeda Pharmaceutical Business Overview
Table 91. Takeda Pharmaceutical Ophthalmology Disorders Drug Product
Table 92. Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 93. Takeda Pharmaceutical Recent Developments
Table 94. Roche Company Details
Table 95. Roche Business Overview
Table 96. Roche Ophthalmology Disorders Drug Product
Table 97. Roche Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 98. Roche Recent Developments
Table 99. Pfizer Company Details
Table 100. Pfizer Business Overview
Table 101. Pfizer Ophthalmology Disorders Drug Product
Table 102. Pfizer Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 103. Pfizer Recent Developments
Table 104. Allergan Company Details
Table 105. Allergan Business Overview
Table 106. Allergan Ophthalmology Disorders Drug Product
Table 107. Allergan Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 108. Allergan Recent Developments
Table 109. Gilead Sciences Company Details
Table 110. Gilead Sciences Business Overview
Table 111. Gilead Sciences Ophthalmology Disorders Drug Product
Table 112. Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 113. Gilead Sciences Recent Developments
Table 114. Kubota Pharmaceutical Company Details
Table 115. Kubota Pharmaceutical Business Overview
Table 116. Kubota Pharmaceutical Ophthalmology Disorders Drug Product
Table 117. Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 118. Kubota Pharmaceutical Recent Developments
Table 119. Alkeus Pharmaceuticals Company Details
Table 120. Alkeus Pharmaceuticals Business Overview
Table 121. Alkeus Pharmaceuticals Ophthalmology Disorders Drug Product
Table 122. Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 123. Alkeus Pharmaceuticals Recent Developments
Table 124. Astellas Pharma Company Details
Table 125. Astellas Pharma Business Overview
Table 126. Astellas Pharma Ophthalmology Disorders Drug Product
Table 127. Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 128. Astellas Pharma Recent Developments
Table 129. Ferrer Corporate Company Details
Table 130. Ferrer Corporate Business Overview
Table 131. Ferrer Corporate Ophthalmology Disorders Drug Product
Table 132. Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 133. Ferrer Corporate Recent Developments
Table 134. Amgen Inc Company Details
Table 135. Amgen Inc Business Overview
Table 136. Amgen Inc Ophthalmology Disorders Drug Product
Table 137. Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 138. Amgen Inc Recent Developments
Table 139. Editas Medicine Inc Company Details
Table 140. Editas Medicine Inc Business Overview
Table 141. Editas Medicine Inc Ophthalmology Disorders Drug Product
Table 142. Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 143. Editas Medicine Inc Recent Developments
Table 144. ProQR Therapeutics NV Company Details
Table 145. ProQR Therapeutics NV Business Overview
Table 146. ProQR Therapeutics NV Ophthalmology Disorders Drug Product
Table 147. ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 148. ProQR Therapeutics NV Recent Developments
Table 149. ReNeuron Company Details
Table 150. ReNeuron Business Overview
Table 151. ReNeuron Ophthalmology Disorders Drug Product
Table 152. ReNeuron Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 153. ReNeuron Recent Developments
Table 154. Amarantus BioScience Company Details
Table 155. Amarantus BioScience Business Overview
Table 156. Amarantus BioScience Ophthalmology Disorders Drug Product
Table 157. Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 158. Amarantus BioScience Recent Developments
Table 159. Ocugen Company Details
Table 160. Ocugen Business Overview
Table 161. Ocugen Ophthalmology Disorders Drug Product
Table 162. Ocugen Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 163. Ocugen Recent Developments
Table 164. ReGenX Biosciences Company Details
Table 165. ReGenX Biosciences Business Overview
Table 166. ReGenX Biosciences Ophthalmology Disorders Drug Product
Table 167. ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 168. ReGenX Biosciences Recent Developments
Table 169. Sucampo Pharmaceuticals Company Details
Table 170. Sucampo Pharmaceuticals Business Overview
Table 171. Sucampo Pharmaceuticals Ophthalmology Disorders Drug Product
Table 172. Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 173. Sucampo Pharmaceuticals Recent Developments
Table 174. Orphagen Pharmaceuticals Company Details
Table 175. Orphagen Pharmaceuticals Business Overview
Table 176. Orphagen Pharmaceuticals Ophthalmology Disorders Drug Product
Table 177. Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 178. Orphagen Pharmaceuticals Recent Developments
Table 179. Okuvision Company Details
Table 180. Okuvision Business Overview
Table 181. Okuvision Ophthalmology Disorders Drug Product
Table 182. Okuvision Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 183. Okuvision Recent Developments
Table 184. Second Sight Medical Company Details
Table 185. Second Sight Medical Business Overview
Table 186. Second Sight Medical Ophthalmology Disorders Drug Product
Table 187. Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 188. Second Sight Medical Recent Developments
Table 189. Acucela Company Details
Table 190. Acucela Business Overview
Table 191. Acucela Ophthalmology Disorders Drug Product
Table 192. Acucela Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 193. Acucela Recent Developments
Table 194. Stealth BioTherapeutics Company Details
Table 195. Stealth BioTherapeutics Business Overview
Table 196. Stealth BioTherapeutics Ophthalmology Disorders Drug Product
Table 197. Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 198. Stealth BioTherapeutics Recent Developments
Table 199. Sun Pharma Advanced Research Company Company Details
Table 200. Sun Pharma Advanced Research Company Business Overview
Table 201. Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Product
Table 202. Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 203. Sun Pharma Advanced Research Company Recent Developments
Table 204. AmpliPhi Biosciences Company Details
Table 205. AmpliPhi Biosciences Business Overview
Table 206. AmpliPhi Biosciences Ophthalmology Disorders Drug Product
Table 207. AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 208. AmpliPhi Biosciences Recent Developments
Table 209. Applied Genetic Technologies Company Details
Table 210. Applied Genetic Technologies Business Overview
Table 211. Applied Genetic Technologies Ophthalmology Disorders Drug Product
Table 212. Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 213. Applied Genetic Technologies Recent Developments
Table 214. Asklepios BioPharmaceutical Company Details
Table 215. Asklepios BioPharmaceutical Business Overview
Table 216. Asklepios BioPharmaceutical Ophthalmology Disorders Drug Product
Table 217. Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 218. Asklepios BioPharmaceutical Recent Developments
Table 219. Biovista Company Details
Table 220. Biovista Business Overview
Table 221. Biovista Ophthalmology Disorders Drug Product
Table 222. Biovista Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 223. Biovista Recent Developments
Table 224. Spark Therapeutics Company Details
Table 225. Spark Therapeutics Business Overview
Table 226. Spark Therapeutics Ophthalmology Disorders Drug Product
Table 227. Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 228. Spark Therapeutics Recent Developments
Table 229. Caladrius Biosciences Company Details
Table 230. Caladrius Biosciences Business Overview
Table 231. Caladrius Biosciences Ophthalmology Disorders Drug Product
Table 232. Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 233. Caladrius Biosciences Recent Developments
Table 234. Dompe Farmaceutici Company Details
Table 235. Dompe Farmaceutici Business Overview
Table 236. Dompe Farmaceutici Ophthalmology Disorders Drug Product
Table 237. Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 238. Dompe Farmaceutici Recent Developments
Table 239. Dormant Projects Company Details
Table 240. Dormant Projects Business Overview
Table 241. Dormant Projects Ophthalmology Disorders Drug Product
Table 242. Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 243. Dormant Projects Recent Development
Table 244. Grupo Ferrer Internacional Company Details
Table 245. Grupo Ferrer Internacional Business Overview
Table 246. Grupo Ferrer Internacional Ophthalmology Disorders Drug Product
Table 247. Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 248. Grupo Ferrer Internacional Recent Development
Table 249. ID Pharma Company Details
Table 250. ID Pharma Business Overview
Table 251. ID Pharma Ophthalmology Disorders Drug Product
Table 252. ID Pharma Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 253. ID Pharma Recent Development
Table 254. InFlectis BioScience Company Details
Table 255. InFlectis BioScience Business Overview
Table 256. InFlectis BioScience Ophthalmology Disorders Drug Product
Table 257. InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 258. InFlectis BioScience Recent Development
Table 259. Ionis Pharmaceuticals Company Details
Table 260. Ionis Pharmaceuticals Business Overview
Table 261. Ionis Pharmaceuticals Ophthalmology Disorders Drug Product
Table 262. Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 263. Ionis Pharmaceuticals Recent Development
Table 264. Research Programs/Design for This Report
Table 265. Key Data Information from Secondary Sources
Table 266. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ophthalmology Disorders Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Ophthalmology Disorders Drug Market Share by Type: 2023 VS 2030
Figure 3. Oral Features
Figure 4. Injection Features
Figure 5. External Use Features
Figure 6. Global Ophthalmology Disorders Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 7. Global Ophthalmology Disorders Drug Market Share by Application: 2023 VS 2030
Figure 8. Juvenile Macular Degeneration (Stargardt Disease) Case Studies
Figure 9. Leber Congenital Amaurosis (LCA) Case Studies
Figure 10. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Case Studies
Figure 11. Usher Syndrome Case Studies
Figure 12. Retinitis Pigmentosa (Retinitis) Case Studies
Figure 13. Ophthalmology Disorders Drug Report Years Considered
Figure 14. Global Ophthalmology Disorders Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Ophthalmology Disorders Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Ophthalmology Disorders Drug Market Share by Region: 2023 VS 2030
Figure 17. Global Ophthalmology Disorders Drug Market Share by Players in 2023
Figure 18. Global Top Ophthalmology Disorders Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ophthalmology Disorders Drug as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Ophthalmology Disorders Drug Revenue in 2023
Figure 20. North America Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Ophthalmology Disorders Drug Market Share by Type (2019-2030)
Figure 22. North America Ophthalmology Disorders Drug Market Share by Application (2019-2030)
Figure 23. North America Ophthalmology Disorders Drug Market Share by Country (2019-2030)
Figure 24. United States Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Ophthalmology Disorders Drug Market Size YoY (2019-2030) & (US$ Million)
Figure 27. Europe Ophthalmology Disorders Drug Market Share by Type (2019-2030)
Figure 28. Europe Ophthalmology Disorders Drug Market Share by Application (2019-2030)
Figure 29. Europe Ophthalmology Disorders Drug Market Share by Country (2019-2030)
Figure 30. Germany Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. France Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. U.K. Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Italy Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Russia Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Nordic Countries Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. China Ophthalmology Disorders Drug Market Size YoY (2019-2030) & (US$ Million)
Figure 37. China Ophthalmology Disorders Drug Market Share by Type (2019-2030)
Figure 38. China Ophthalmology Disorders Drug Market Share by Application (2019-2030)
Figure 39. Asia Ophthalmology Disorders Drug Market Size YoY (2019-2030) & (US$ Million)
Figure 40. Asia Ophthalmology Disorders Drug Market Share by Type (2019-2030)
Figure 41. Asia Ophthalmology Disorders Drug Market Share by Application (2019-2030)
Figure 42. Asia Ophthalmology Disorders Drug Market Share by Region (2019-2030)
Figure 43. Japan Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. South Korea Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. China Taiwan Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. India Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Australia Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size YoY (2019-2030) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Share by Type (2019-2030)
Figure 51. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Share by Application (2019-2030)
Figure 52. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Share by Country (2019-2030)
Figure 53. Brazil Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Mexico Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. Turkey Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 57. Israel Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 58. GCC Countries Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 59. Sanofi Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 60. Bayer Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 61. Bausch + Lomb Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 62. Novartis Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 63. Usher Syndrome Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 64. Takeda Pharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 65. Roche Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 66. Pfizer Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 67. Allergan Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 68. Gilead Sciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 69. Kubota Pharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 70. Alkeus Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 71. Astellas Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 72. Ferrer Corporate Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 73. Amgen Inc Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 74. Editas Medicine Inc Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 75. ProQR Therapeutics NV Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 76. ReNeuron Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 77. Amarantus BioScience Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 78. Ocugen Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 79. ReGenX Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 80. Sucampo Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 81. Orphagen Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 82. Okuvision Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 83. Second Sight Medical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 84. Acucela Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 85. Stealth BioTherapeutics Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 86. Sun Pharma Advanced Research Company Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 87. AmpliPhi Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 88. Applied Genetic Technologies Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 89. Asklepios BioPharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 90. Biovista Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 91. Spark Therapeutics Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 92. Caladrius Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 93. Dompe Farmaceutici Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 94. Dormant Projects Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 95. Grupo Ferrer Internacional Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 96. ID Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 97. InFlectis BioScience Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 98. Ionis Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 99. Ixchel Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 100. Khondrion Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 101. Mimetogen Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 102. Mitotech Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 103. M's Science Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 104. Nanovector Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 105. SanBio Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 106. Bottom-up and Top-down Approaches for This Report_x
Table 1. Global Ophthalmology Disorders Drug Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of Oral
Table 3. Key Players of Injection
Table 4. Key Players of External Use
Table 5. Global Ophthalmology Disorders Drug Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 6. Global Ophthalmology Disorders Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Ophthalmology Disorders Drug Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Ophthalmology Disorders Drug Market Share by Region (2019-2024)
Table 9. Global Ophthalmology Disorders Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Ophthalmology Disorders Drug Market Share by Region (2025-2030)
Table 11. Ophthalmology Disorders Drug Market Trends
Table 12. Ophthalmology Disorders Drug Market Drivers
Table 13. Ophthalmology Disorders Drug Market Challenges
Table 14. Ophthalmology Disorders Drug Market Restraints
Table 15. Global Ophthalmology Disorders Drug Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Ophthalmology Disorders Drug Revenue Share by Players (2019-2024)
Table 17. Global Top Ophthalmology Disorders Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ophthalmology Disorders Drug as of 2023)
Table 18. Global Ophthalmology Disorders Drug Industry Ranking 2022 VS 2023 VS 2024
Table 19. Global 5 Largest Players Market Share by Ophthalmology Disorders Drug Revenue (CR5 and HHI) & (2019-2024)
Table 20. Global Key Players of Ophthalmology Disorders Drug, Headquarters and Area Served
Table 21. Global Key Players of Ophthalmology Disorders Drug, Product and Application
Table 22. Global Key Players of Ophthalmology Disorders Drug, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2019-2024)
Table 26. Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2025-2030)
Table 28. Global Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Ophthalmology Disorders Drug Revenue Share by Application (2019-2024)
Table 30. Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Ophthalmology Disorders Drug Revenue Share by Application (2025-2030)
Table 32. North America Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 33. North America Ophthalmology Disorders Drug Market Size by Type (2025-2030) & (US$ Million)
Table 34. North America Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 35. North America Ophthalmology Disorders Drug Market Size by Application (2025-2030) & (US$ Million)
Table 36. North America Ophthalmology Disorders Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Ophthalmology Disorders Drug Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Ophthalmology Disorders Drug Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 40. Europe Ophthalmology Disorders Drug Market Size by Type (2025-2030) & (US$ Million)
Table 41. Europe Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 42. Europe Ophthalmology Disorders Drug Market Size by Application (2025-2030) & (US$ Million)
Table 43. Europe Ophthalmology Disorders Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Europe Ophthalmology Disorders Drug Market Size by Country (2019-2024) & (US$ Million)
Table 45. Europe Ophthalmology Disorders Drug Market Size by Country (2025-2030) & (US$ Million)
Table 46. China Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 47. China Ophthalmology Disorders Drug Market Size by Type (2025-2030) & (US$ Million)
Table 48. China Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 49. China Ophthalmology Disorders Drug Market Size by Application (2025-2030) & (US$ Million)
Table 50. Asia Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 51. Asia Ophthalmology Disorders Drug Market Size by Type (2025-2030) & (US$ Million)
Table 52. Asia Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 53. Asia Ophthalmology Disorders Drug Market Size by Application (2025-2030) & (US$ Million)
Table 54. Asia Ophthalmology Disorders Drug Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 55. Asia Ophthalmology Disorders Drug Market Size by Region (2019-2024) & (US$ Million)
Table 56. Asia Ophthalmology Disorders Drug Market Size by Region (2025-2030) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Type (2019-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Type (2025-2030) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Application (2019-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Application (2025-2030) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 62. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country (2019-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size by Country (2025-2030) & (US$ Million)
Table 64. Sanofi Company Details
Table 65. Sanofi Business Overview
Table 66. Sanofi Ophthalmology Disorders Drug Product
Table 67. Sanofi Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 68. Sanofi Recent Developments
Table 69. Bayer Company Details
Table 70. Bayer Business Overview
Table 71. Bayer Ophthalmology Disorders Drug Product
Table 72. Bayer Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 73. Bayer Recent Developments
Table 74. Bausch + Lomb Company Details
Table 75. Bausch + Lomb Business Overview
Table 76. Bausch + Lomb Ophthalmology Disorders Drug Product
Table 77. Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 78. Bausch + Lomb Recent Developments
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Ophthalmology Disorders Drug Product
Table 82. Novartis Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 83. Novartis Recent Developments
Table 84. Usher Syndrome Company Details
Table 85. Usher Syndrome Business Overview
Table 86. Usher Syndrome Ophthalmology Disorders Drug Product
Table 87. Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 88. Usher Syndrome Recent Developments
Table 89. Takeda Pharmaceutical Company Details
Table 90. Takeda Pharmaceutical Business Overview
Table 91. Takeda Pharmaceutical Ophthalmology Disorders Drug Product
Table 92. Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 93. Takeda Pharmaceutical Recent Developments
Table 94. Roche Company Details
Table 95. Roche Business Overview
Table 96. Roche Ophthalmology Disorders Drug Product
Table 97. Roche Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 98. Roche Recent Developments
Table 99. Pfizer Company Details
Table 100. Pfizer Business Overview
Table 101. Pfizer Ophthalmology Disorders Drug Product
Table 102. Pfizer Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 103. Pfizer Recent Developments
Table 104. Allergan Company Details
Table 105. Allergan Business Overview
Table 106. Allergan Ophthalmology Disorders Drug Product
Table 107. Allergan Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 108. Allergan Recent Developments
Table 109. Gilead Sciences Company Details
Table 110. Gilead Sciences Business Overview
Table 111. Gilead Sciences Ophthalmology Disorders Drug Product
Table 112. Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 113. Gilead Sciences Recent Developments
Table 114. Kubota Pharmaceutical Company Details
Table 115. Kubota Pharmaceutical Business Overview
Table 116. Kubota Pharmaceutical Ophthalmology Disorders Drug Product
Table 117. Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 118. Kubota Pharmaceutical Recent Developments
Table 119. Alkeus Pharmaceuticals Company Details
Table 120. Alkeus Pharmaceuticals Business Overview
Table 121. Alkeus Pharmaceuticals Ophthalmology Disorders Drug Product
Table 122. Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 123. Alkeus Pharmaceuticals Recent Developments
Table 124. Astellas Pharma Company Details
Table 125. Astellas Pharma Business Overview
Table 126. Astellas Pharma Ophthalmology Disorders Drug Product
Table 127. Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 128. Astellas Pharma Recent Developments
Table 129. Ferrer Corporate Company Details
Table 130. Ferrer Corporate Business Overview
Table 131. Ferrer Corporate Ophthalmology Disorders Drug Product
Table 132. Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 133. Ferrer Corporate Recent Developments
Table 134. Amgen Inc Company Details
Table 135. Amgen Inc Business Overview
Table 136. Amgen Inc Ophthalmology Disorders Drug Product
Table 137. Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 138. Amgen Inc Recent Developments
Table 139. Editas Medicine Inc Company Details
Table 140. Editas Medicine Inc Business Overview
Table 141. Editas Medicine Inc Ophthalmology Disorders Drug Product
Table 142. Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 143. Editas Medicine Inc Recent Developments
Table 144. ProQR Therapeutics NV Company Details
Table 145. ProQR Therapeutics NV Business Overview
Table 146. ProQR Therapeutics NV Ophthalmology Disorders Drug Product
Table 147. ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 148. ProQR Therapeutics NV Recent Developments
Table 149. ReNeuron Company Details
Table 150. ReNeuron Business Overview
Table 151. ReNeuron Ophthalmology Disorders Drug Product
Table 152. ReNeuron Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 153. ReNeuron Recent Developments
Table 154. Amarantus BioScience Company Details
Table 155. Amarantus BioScience Business Overview
Table 156. Amarantus BioScience Ophthalmology Disorders Drug Product
Table 157. Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 158. Amarantus BioScience Recent Developments
Table 159. Ocugen Company Details
Table 160. Ocugen Business Overview
Table 161. Ocugen Ophthalmology Disorders Drug Product
Table 162. Ocugen Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 163. Ocugen Recent Developments
Table 164. ReGenX Biosciences Company Details
Table 165. ReGenX Biosciences Business Overview
Table 166. ReGenX Biosciences Ophthalmology Disorders Drug Product
Table 167. ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 168. ReGenX Biosciences Recent Developments
Table 169. Sucampo Pharmaceuticals Company Details
Table 170. Sucampo Pharmaceuticals Business Overview
Table 171. Sucampo Pharmaceuticals Ophthalmology Disorders Drug Product
Table 172. Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 173. Sucampo Pharmaceuticals Recent Developments
Table 174. Orphagen Pharmaceuticals Company Details
Table 175. Orphagen Pharmaceuticals Business Overview
Table 176. Orphagen Pharmaceuticals Ophthalmology Disorders Drug Product
Table 177. Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 178. Orphagen Pharmaceuticals Recent Developments
Table 179. Okuvision Company Details
Table 180. Okuvision Business Overview
Table 181. Okuvision Ophthalmology Disorders Drug Product
Table 182. Okuvision Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 183. Okuvision Recent Developments
Table 184. Second Sight Medical Company Details
Table 185. Second Sight Medical Business Overview
Table 186. Second Sight Medical Ophthalmology Disorders Drug Product
Table 187. Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 188. Second Sight Medical Recent Developments
Table 189. Acucela Company Details
Table 190. Acucela Business Overview
Table 191. Acucela Ophthalmology Disorders Drug Product
Table 192. Acucela Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 193. Acucela Recent Developments
Table 194. Stealth BioTherapeutics Company Details
Table 195. Stealth BioTherapeutics Business Overview
Table 196. Stealth BioTherapeutics Ophthalmology Disorders Drug Product
Table 197. Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 198. Stealth BioTherapeutics Recent Developments
Table 199. Sun Pharma Advanced Research Company Company Details
Table 200. Sun Pharma Advanced Research Company Business Overview
Table 201. Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Product
Table 202. Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 203. Sun Pharma Advanced Research Company Recent Developments
Table 204. AmpliPhi Biosciences Company Details
Table 205. AmpliPhi Biosciences Business Overview
Table 206. AmpliPhi Biosciences Ophthalmology Disorders Drug Product
Table 207. AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 208. AmpliPhi Biosciences Recent Developments
Table 209. Applied Genetic Technologies Company Details
Table 210. Applied Genetic Technologies Business Overview
Table 211. Applied Genetic Technologies Ophthalmology Disorders Drug Product
Table 212. Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 213. Applied Genetic Technologies Recent Developments
Table 214. Asklepios BioPharmaceutical Company Details
Table 215. Asklepios BioPharmaceutical Business Overview
Table 216. Asklepios BioPharmaceutical Ophthalmology Disorders Drug Product
Table 217. Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 218. Asklepios BioPharmaceutical Recent Developments
Table 219. Biovista Company Details
Table 220. Biovista Business Overview
Table 221. Biovista Ophthalmology Disorders Drug Product
Table 222. Biovista Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 223. Biovista Recent Developments
Table 224. Spark Therapeutics Company Details
Table 225. Spark Therapeutics Business Overview
Table 226. Spark Therapeutics Ophthalmology Disorders Drug Product
Table 227. Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 228. Spark Therapeutics Recent Developments
Table 229. Caladrius Biosciences Company Details
Table 230. Caladrius Biosciences Business Overview
Table 231. Caladrius Biosciences Ophthalmology Disorders Drug Product
Table 232. Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 233. Caladrius Biosciences Recent Developments
Table 234. Dompe Farmaceutici Company Details
Table 235. Dompe Farmaceutici Business Overview
Table 236. Dompe Farmaceutici Ophthalmology Disorders Drug Product
Table 237. Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 238. Dompe Farmaceutici Recent Developments
Table 239. Dormant Projects Company Details
Table 240. Dormant Projects Business Overview
Table 241. Dormant Projects Ophthalmology Disorders Drug Product
Table 242. Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 243. Dormant Projects Recent Development
Table 244. Grupo Ferrer Internacional Company Details
Table 245. Grupo Ferrer Internacional Business Overview
Table 246. Grupo Ferrer Internacional Ophthalmology Disorders Drug Product
Table 247. Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 248. Grupo Ferrer Internacional Recent Development
Table 249. ID Pharma Company Details
Table 250. ID Pharma Business Overview
Table 251. ID Pharma Ophthalmology Disorders Drug Product
Table 252. ID Pharma Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 253. ID Pharma Recent Development
Table 254. InFlectis BioScience Company Details
Table 255. InFlectis BioScience Business Overview
Table 256. InFlectis BioScience Ophthalmology Disorders Drug Product
Table 257. InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 258. InFlectis BioScience Recent Development
Table 259. Ionis Pharmaceuticals Company Details
Table 260. Ionis Pharmaceuticals Business Overview
Table 261. Ionis Pharmaceuticals Ophthalmology Disorders Drug Product
Table 262. Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024) & (US$ Million)
Table 263. Ionis Pharmaceuticals Recent Development
Table 264. Research Programs/Design for This Report
Table 265. Key Data Information from Secondary Sources
Table 266. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ophthalmology Disorders Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Ophthalmology Disorders Drug Market Share by Type: 2023 VS 2030
Figure 3. Oral Features
Figure 4. Injection Features
Figure 5. External Use Features
Figure 6. Global Ophthalmology Disorders Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 7. Global Ophthalmology Disorders Drug Market Share by Application: 2023 VS 2030
Figure 8. Juvenile Macular Degeneration (Stargardt Disease) Case Studies
Figure 9. Leber Congenital Amaurosis (LCA) Case Studies
Figure 10. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Case Studies
Figure 11. Usher Syndrome Case Studies
Figure 12. Retinitis Pigmentosa (Retinitis) Case Studies
Figure 13. Ophthalmology Disorders Drug Report Years Considered
Figure 14. Global Ophthalmology Disorders Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Ophthalmology Disorders Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Ophthalmology Disorders Drug Market Share by Region: 2023 VS 2030
Figure 17. Global Ophthalmology Disorders Drug Market Share by Players in 2023
Figure 18. Global Top Ophthalmology Disorders Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ophthalmology Disorders Drug as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Ophthalmology Disorders Drug Revenue in 2023
Figure 20. North America Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Ophthalmology Disorders Drug Market Share by Type (2019-2030)
Figure 22. North America Ophthalmology Disorders Drug Market Share by Application (2019-2030)
Figure 23. North America Ophthalmology Disorders Drug Market Share by Country (2019-2030)
Figure 24. United States Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Ophthalmology Disorders Drug Market Size YoY (2019-2030) & (US$ Million)
Figure 27. Europe Ophthalmology Disorders Drug Market Share by Type (2019-2030)
Figure 28. Europe Ophthalmology Disorders Drug Market Share by Application (2019-2030)
Figure 29. Europe Ophthalmology Disorders Drug Market Share by Country (2019-2030)
Figure 30. Germany Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. France Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. U.K. Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Italy Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Russia Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Nordic Countries Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. China Ophthalmology Disorders Drug Market Size YoY (2019-2030) & (US$ Million)
Figure 37. China Ophthalmology Disorders Drug Market Share by Type (2019-2030)
Figure 38. China Ophthalmology Disorders Drug Market Share by Application (2019-2030)
Figure 39. Asia Ophthalmology Disorders Drug Market Size YoY (2019-2030) & (US$ Million)
Figure 40. Asia Ophthalmology Disorders Drug Market Share by Type (2019-2030)
Figure 41. Asia Ophthalmology Disorders Drug Market Share by Application (2019-2030)
Figure 42. Asia Ophthalmology Disorders Drug Market Share by Region (2019-2030)
Figure 43. Japan Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. South Korea Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. China Taiwan Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. India Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Australia Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Size YoY (2019-2030) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Share by Type (2019-2030)
Figure 51. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Share by Application (2019-2030)
Figure 52. Middle East, Africa, and Latin America Ophthalmology Disorders Drug Market Share by Country (2019-2030)
Figure 53. Brazil Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Mexico Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. Turkey Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 57. Israel Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 58. GCC Countries Ophthalmology Disorders Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 59. Sanofi Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 60. Bayer Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 61. Bausch + Lomb Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 62. Novartis Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 63. Usher Syndrome Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 64. Takeda Pharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 65. Roche Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 66. Pfizer Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 67. Allergan Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 68. Gilead Sciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 69. Kubota Pharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 70. Alkeus Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 71. Astellas Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 72. Ferrer Corporate Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 73. Amgen Inc Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 74. Editas Medicine Inc Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 75. ProQR Therapeutics NV Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 76. ReNeuron Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 77. Amarantus BioScience Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 78. Ocugen Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 79. ReGenX Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 80. Sucampo Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 81. Orphagen Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 82. Okuvision Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 83. Second Sight Medical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 84. Acucela Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 85. Stealth BioTherapeutics Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 86. Sun Pharma Advanced Research Company Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 87. AmpliPhi Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 88. Applied Genetic Technologies Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 89. Asklepios BioPharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 90. Biovista Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 91. Spark Therapeutics Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 92. Caladrius Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 93. Dompe Farmaceutici Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 94. Dormant Projects Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 95. Grupo Ferrer Internacional Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 96. ID Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 97. InFlectis BioScience Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 98. Ionis Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 99. Ixchel Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 100. Khondrion Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 101. Mimetogen Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 102. Mitotech Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 103. M's Science Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 104. Nanovector Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 105. SanBio Revenue Growth Rate in Ophthalmology Disorders Drug Business (2019-2024)
Figure 106. Bottom-up and Top-down Approaches for This Report_x
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Circuit Simulator Market Research Report 2025
Mar 11, 25
Global Schematic Editor Market Research Report 2025
Mar 11, 25
Global Milk Green Tea Market Research Report 2025
Mar 11, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232